BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join
back to Directory

Micar Innovation

Micar Innovation logo

Website
http://micar21.com
Founded
2016
Patents
1
Publications
5

Technologies

AI Companies (Drug Discovery)

Micar Innovation is a drug discovery engine. Micar Innovation creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity through pre-negotiated acquisitions.
Drug discovery operations are built around an experienced team of researchers. Previous accomplishments of Micar Innovation team members led to multiple marketed and clinical-stage drugs in diverse disease areas including neurology, oncology, arthritis. Micar Innovation business model includes “Build-to-Buy” partnerships, where world-class academic researchers are matched with pharmaceutical partners to form new drug discovery programs for the Micar Innovation team to execute upon. New start-up companies are spun-out for translation of these programs into novel therapies, incorporating an exclusive option for a pharmaceutical partner to acquire a spun-out company downstream at pre-set terms. Micar Innovation has now formed multiple companies around discovery programs subject to Build-to-Buy agreements.

#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

 

R&D Platform

We successfully integrated the sate-of-art in silico and experimental approaches and already identified new promising drug candidates. Micar Innovation can help discover and than predict the effectiveness of new potential drug molecules, reducing the need for costly and time-consuming physical synthesis and testing.

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.